Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Duration of initial disease response remains a strong prognostic factor in multiple myeloma (MM) particularly for upfront autologous hematopoietic cell transplant (AHCT) recipients. We hypothesized that new drug classes and combinations employed prior to AHCT as well as after post-AHCT relapse may have changed the natural history of MM in this population. We analyzed the Center for International Blood and Marrow Transplant Research database to track overall survival (OS) of MM patients receiving single AHCT within 12 months after diagnosis (N=3256) and relapsing early post-AHCT (<24 months), and to identify factors predicting for early vs late relapses (24−48 months post-AHCT). Over three periods (2001–2004, 2005–2008, 2009–2013), patient characteristics were balanced except for lower proportion of Stage III, higher likelihood of one induction therapy with novel triplets and higher rates of planned post-AHCT maintenance over time. The proportion of patients relapsing early was stable over time at 35–38%. Factors reducing risk of early relapse included lower stage, chemosensitivity, transplant after 2008 and post-AHCT maintenance. Shorter post-relapse OS was associated with early relapse, IgA MM, Karnofsky <90, stage III, >1 line of induction and lack of maintenance. Post-AHCT early relapse remains a poor prognostic factor, even though outcomes have improved over time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632 · cited 1×
“Median follow-up of survivors was 120 (3-170) months for 2001-2004, 86 (3-129) months for 2005-2008 and 39 (3-82) months for 2009-2013 groups.”
Self-citationPalumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210
Self-citationLenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257 · cited 5×
“PR 635 (71) 1069 (76) 408 (43) MR/NR/SD 98 (11) 113 (8) 36 (4) Relapse/Progression 21 (2) 42 (3) 17 (2) Unknown 3 (<1) 0 0 Sensitivity to chemotherapy Sensitive 774 (86) 1246 (89) 906 (94) Resistant 119 (13) 155 (11) 53 (6) Unknown 3 (<1) 0 0 Time from diagnosis to transplant < 6 months 284 (32) 391 (28) 399 (42) 6 –…”
InfluentialLenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155 · cited 2×
“Variable Relapse <24 months Relapse after 24 months No Relapse Chemotherapy VTD 98 (8) 93 (9) 64 (7) RVD 181 (16) 94 (10) 211 (24) CVD 80 (7) 63 (6) 72 (8) VD 76 (7) 55 (6) 79 (9) RD 134 (12) 88 (9) 103 (12) TD 234 (20) 276 (28) 152 (17) VAD/similar 353 (31) 315 (32) 212 (24) Melphalan dose (mg/m2) for condition regim…”
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Self-citationSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984 · cited 3×
“56) Disease status at transplant CR 142 (12) 140 (14) 171 (19) PR 860 (74) 760 (77) 652 (73) MR/NR/SD 108 (9) 67 (7) 56 (6) Relapse/Progression 45 (4) 16 (2) 14 (2) Unknown 1 (<1) 1 (<1) 0 Sensitivity to chemotherapy Sensitive 1002 (87) 900 (91) 823 (92) Resistant 153 (13) 83 (8) 70 (8) Unknown 1 (<1) 1 (<1) 0 Time fr…”
Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908
Self-citationSonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6820 · Cited by 824
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
Palumbo, A., Cavallo, F., Gay, F., Di Raimondo, F., Ben Yehuda, D., Petrucci, M. T., Pezzatti, S., Caravita, T., Cerrato, C., Ribakovsky, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402888 · Cited by 778
McCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6679 · Cited by 698
Research works printed but not linked: 23
- Laubach J, Kumar S . Management of transplant-eligible patients with newly diagnosed multiple myeloma. Cancer Treat Res 2016; 169: 145–167. · DOI
- Costa LJ, Zhang M-J, Zhong X, Dispenzieri A, Lonial S, Krishnan A et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 1615–1624. · DOI
- Hari PN, McCarthy PL . Multiple myeloma: future directions in autologous transplantation and novel agents. Biol Blood Marrow Transplant 2013; 19: S20–S25. · DOI
- Schiffer CA, Zonder JA . Transplantation for myeloma—now or later? N Engl J Med 2017; 376: 1378–1379. · DOI
- Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122–1128. · DOI · Paper page
- D'Souza A, Zhang MJ, Huang J, Fei M, Pasquini M, Hamadani M et al. Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014. Leukemia 2017; 31: 1998–2000. · DOI
- Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V . Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents. Bone Marrow Transplant 2015; 50: 204–208. · DOI
- Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia 2016; 30: 2208–2213. · DOI
- Palumbo A, Bringhen S, Falco P, Cavallo F, Ambrosini MT, Avonto I et al. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Cancer 2007; 110: 824–829. · DOI
- Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK et al. Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant 2008; 42: 413–420. · DOI
- Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI et al. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant 2013; 19: 760–766. · DOI
- Dispenzieri A . Myeloma: management of the newly diagnosed high-risk patient. Hematology Am Soc Hematol Educ Program 2016; 2016: 485–494. · DOI
- Kuiper R, van Duin M, van Vliet MH, Broijl A, van der Holt B, El Jarari L et al. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood 2015; 126: 1996–2004. · DOI
- Lonial S, Boise LH, Kaufman J . How I treat high-risk myeloma. Blood 2015; 126: 1536–1543. · DOI
- Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D et al. Post-transplant outcomes in high-risk compared with non-high-risk multiple myeloma: a CIBMTR analysis. Biol Blood Marrow Transplant 2016; 22: 1893–1899. · DOI
- Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016; 127: 2955–2962. · DOI · Paper page
- Voorhees PM, Usmani SZ . The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy. Clin Adv Hematol Oncol 2016; 14: 719–728.
- McCarthy PL, Einsele H, Attal M, Giralt S . The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients. Exp Rev Hematol 2014; 7: 55–66. · DOI
- Krishnan A, Vij R, Keller J, Dhakal B, Hari P . Moving beyond autologous transplantation in multiple myeloma: consolidation, maintenance, allogeneic transplant, and immune therapy. Am Soc Clin Oncol Educ Book 2016; 35: 210–221. · DOI
- Mohty M, Richardson PG, McCarthy PL, Attal M . Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand? Bone Marrow Transplantation 2015; 50: 1024–1029. · DOI
- Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol 2014; 32: 2712–2717. · DOI · Paper page
- Nooka AK, Kaufman JL, Muppidi S, Langston A, Heffner LT, Gleason C et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia 2014; 28: 690–693. · DOI · Paper page
- Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc 2013; 88: 360–376. · DOI · Paper page
Cited by
van de Donk, N. W. C. J., Pawlyn, C., & Yong, K. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 869
The multiple myelomas — current concepts in cytogenetic classification and therapy
Kumar, S. K., & Rajkumar, S. V. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0018-y · Cited by 302
Self-citationMultiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Costello, C., Efebera, Y., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0057 · Cited by 277
Self-citationCohen, Y. C., Zada, M., Wang, S.-Y., Bornstein, C., David, E., Moshe, A., Li, B., Shlomi-Loubaton, S., Gatt, M. E., Gur, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01232-w · Cited by 235
Sequencing multiple myeloma therapies with and after antibody therapies
van de Donk, N. W. C. J. (2020) · Hematology · doi:10.1182/hematology.2020000109 · Cited by 27
Metadata
- Authors
- Kumar, S. K., Dispenzieri, A., Fraser, R., Mingwei, F., Akpek, G., Cornell, R., Kharfan-Dabaja, M., Freytes, C., Hashmi, S., Hildebrandt, G., Holmberg, L., Kyle, R., Lazarus, H., Lee, C., Mikhael, J., Nishihori, T., Tay, J., Usmani, S., Vesole, D., Vij, R., Wirk, B., Krishnan, A., Gasparetto, C., Mark, T., Nieto, Y., Hari, P., & D'Souza, A.
- Venue
- Leukemia
- Published
- 2017-11-16
- Volume
- 32
- Issue
- 4
- Pages
- 986-995
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2774700270
- Cited by
- 92
- References
- 10
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.